After sitting in the Hobart Magistrates Court system for more than four years, construction company Boral Construction ...
D. Boral Capital says CytoSorbents (CTSO) reported a strong Q4, with product revenue growth estimated between 22% and 25% ...
American Resources (NASDAQ:AREC – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research report issued to clients and investors on ...
Fintel reports that on January 13, 2025, D. Boral Capital initiated coverage of CorMedix (NasdaqGM:CRMD) with a Buy recommendation. As of December 23, 2024, the average one-year price target for ...
Boral Capital initiated coverage of Avita Medical (RCEL) with a Buy rating and $25 price target Avita’s Recell technology has shown “promising results” in clinical trials for a variety of ...
D. Boral Capital reissued their buy rating on shares of American Resources (NASDAQ:AREC – Free Report) in a research report released on Tuesday,Benzinga reports. The firm currently has a $4.00 price ...